Although research into urine- and image-based alternatives continues, there is no established replacement for cystoscopy.
Urothelial Carcinoma Diagnostics
Advertisement
Researchers find promise for ctDNA-guided immunotherapy for patients with MIBC who underwent radical cystectomy.
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer.
Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Video Insights
Conference Coverage
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
Advertisement
Advertisement
Trending
Researchers find promise in Gem/Doce as an alternative therapy for patients with NMIBC recurrence after BCG induction.
Drs. Packiam and Yerram conclude with an AI-powered pathology tool designed to predict response to BCG in NMIBC.
Drs. Packiam and Yerram shift focus to SunRISe-1 Cohort 4, which examined BCG-unresponsive papillary disease.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.